CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 81 enrolled
Drug / intervention
Mavacamten +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05174416
NCT05174416Phase 3Completed
CompareCT.gov

A Phase III, Randomized, Double-blinded, Placebo-controlled Clinical Study With A Long-term Extension to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

LianBio LLC·interventional·Posted Dec 30, 2021·Updated Sep 19, 2024

In Brief

A Phase 3 clinical trial evaluating Mavacamten and Placebo for Obstructive Hypertrophic Cardiomyopathy. Completed, enrolled 81 participants across 1 site.

Detailed Summary

Mavacamtenis a novel, small molecule, selective allosteric inhibitor of cardiac-specific myosin, for the treatment of patients with symptomatic oHCM. This study will assess the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Hypertrophic Cardiomyopathy
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedDec 30, 2021
Enrollment StartJan 4, 2022
Primary CompletionMar 6, 2023
Study CompletionJul 22, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.5 years ago

Interventions

Mavacamtendrug

Mavacamten Capsules

Placebodrug

Matching PBO capsules during placebo controlled period，and mavacamten capsules during long term extension period